{"task_id": "095009998e56600a", "source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 193/905)", "text": "llow-up and onwards.42\nSeverity assessment in COPD\n\n--- Page 199 ---\n185\nChest medicine\n4 Cochrane meta-analyses (2007) of trials (including TORCH) favour steroids + LABA (long-acting \ue020-agonist) \nvs either alone. LABA alone may \ue000exacerbation rates, but no excess hospitalizations or mortality; steroid \ninhalers alone are associated with \ue000mortality (by 33%) compared with steroids + LABA. 44 Steroid inhalers \nmay \ue000risk of pneumonia, but when combined with LABA, advantages outweigh disadvantages.\nMore advanced COPD\n\ue007Pulmonary rehabilitation is greatly valued by patients.\n  \u2022 Consider LTOT if PaO2 <7.3kPa (see \u2018Long-term O2 therapy\u2019, earlier in topic OPPOSITE).\n  \n\u2022 Surgery may be appropriate in selected patients, eg recurrent pneumothoraces; \nisolated bullous disease. Lung volume reduction/endobronchial valve/transplant.\n  \n\u2022 NIV may be appropriate if hypercapnic on LTOT.\n  \n\u2022 NB: air travel is risky if FEV1 <50% or PaO2 <6.7kPa on air.\n  \n\u2022 Consider palliative care input.\nIndications for specialist referral\n  \n\u2022 Uncertain diagnosis, or suspected severe COPD, or a rapid decline in FEV1.\n  \n\u2022 Onset of cor pulmonale.\n  \n\u2022 Bullous lung disease (to assess for surgery).\n  \n\u2022 Assessment for oral corticosteroids, nebulizer therapy, or LTOT.\n  \n\u2022 <10 pack-years smoking (= the number of packs/day \u2248 years of smoking) or COPD \nin patient <40yrs (eg is the cause \ue0251-antitrypsin de\ufb01 ciency? p290).\n  \n\u2022 Symptoms disproportionate to lung function tests.\n  \n\u2022 Frequent infections (to exclude bronchiectasis).\nBritish Thoracic Society (BTS)/NICE COPD guidelines\nFig 4.14 Management of COPD in primary and secondary care.\n*Tiotropium (LAMA) is more eff ective than salmeterol in preventing exacerbations for patients with \nmoderate-to-very-severe COPD.43\n\u00a9 National Institute for Health and Clinical Excellence 2010. CG101 Chronic obstructive pulmonary \ndisease in over 16s: diagnosis and management. Available from https://www.nice.org.uk/guidance/cg101 .\nNICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to \nregular review and may be updated or withdrawn. \nManagement of COPD\nInitiate short-acting \ue0202-antagonist (SABA)/\nshort-acting muscarinic antagonist (SAMA)\nFEV1 >50%\nLong-acting\n\ue0202-antagonist (LABA)\nFEV1 <50%\nLong-acting muscarinic \nantagonist (LAMA)*,4\nLABA plus inhaled \ncorticosteroid (ICS)\nLABA plus inhaled \ncorticosteroid (ICS) in \ncombined inhaler\nLAMA plus LABA/ICS \ncombination inhaler", "text_length": 2453, "metadata": {"source": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf (Part 193/905)", "type": "chunk", "chunk_index": 192, "total_chunks": 905, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T17:59:52.264208", "document_uuid": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f", "filename": "8205Oxford Handbook of Clinical Medicine 10th 2017 Edition_SamanSarKo - Copy.pdf", "category": "medical_pdf", "section": "body", "year": 2017, "outdated": false, "document_id": "1c4b3c41-9a74-4d3d-ab11-d2a041c9641f"}, "created_at": "2025-12-11T17:59:52.271603", "status": "complete", "chunks_added": 2}